Elritercept, a Modified Activin Receptor IIA Ligand Trap, increased Erythropoiesis and Thrombopoiesis in a Phase 1 Trial.

Autor:	Lachey JL; Keros Therapeutics, Lexington, Massachusetts, United States., Rovaldi C; Keros Therapeutics, Lexington, Massachusetts, United States., Bobba S; Keros Therapeutics, Lexington, Massachusetts, United States., Tur J; Keros Therapeutics, Lexington, Massachusetts, United States., Natarajan HD; Keros Therapeutics, Lexington, Massachusetts, United States., Snyder B; Alfred Health, Elsternwick, VIC, Australia., Seehra J; Keros Therapeutics, Lexington, Massachusetts, United States.
Jazyk:	angličtina
Zdroj:	Blood advances [Blood Adv] 2024 Oct 22. Date of Electronic Publication: 2024 Oct 22.
DOI:	10.1182/bloodadvances.2024014172
Abstrakt:	The TGF-β superfamily plays a crucial role in regulating biological processes of virtually every tissue and system in the body, including hemostasis and hematopoiesis. Elritercept (KER-050) is an investigational, modified activin receptor type IIA ligand trap designed to bind and inhibit activin A and other select TGF-β superfamily ligands including activin B and growth differentiation factor (GDF)-8 and GDF-11. The objectives of this Phase 1 randomized, placebo-controlled study of elritercept were to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamic markers of activin inhibition and hematopoiesis in healthy, post-menopausal women (N=48). This study was comprised of 2 parts: single ascending doses ranging from 0.05 to 4.5 mg/kg, and multiple (up to 2 doses) ascending doses of 0.75 mg/kg administered subcutaneously (SC) every 4 weeks. Elritercept was generally well-tolerated at all dose levels, with no dose limiting toxicities observed. There were no severe or serious adverse events nor clinically significant changes in safety laboratory measures. Serum concentrations increased in dose-proportional manner following single SC doses, with peak concentrations achieved in 4.5 to 6 days and a mean elimination half-life of 12 days. These parameters were comparable following multiple doses. Elritercept elicited rapid, sustained, and dose-dependent increases in reticulocytes, red blood cells, hemoglobin, and platelets without eliciting detrimental changes in white blood cells such as neutrophils and lymphocytes. The time course and duration of changes in these cell populations supported a differentiated pharmacologic profile that is consistent with stimulation of both early- and late-stage hematologic pathways. Australian New Zealand Clinical Trial Registry (ACTRN12619000318189). (Copyright © 2024 American Society of Hematology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu